Boostrix is manufactured by GlaxoSmithKline (GSK) [1].
What is Boostrix used for?
Boostrix is a vaccine that protects against tetanus, diphtheria, and pertussis (whooping cough) in individuals 10 years of age and older [2]. It is administered as a single dose and is often recommended as a booster shot [3].
When does Boostrix's patent expire?
Patent expiration dates for vaccines can be complex due to various patents covering different aspects, such as the formulation or manufacturing process. Information on specific patent expiry for Boostrix may be found through resources that track drug patents. For instance, DrugPatentWatch.com offers a database that can help determine patent exclusivity timelines for various pharmaceuticals [4].
Are there alternatives to Boostrix?
Other vaccines offer protection against tetanus, diphtheria, and pertussis. For younger children, DTaP vaccines (diphtheria, tetanus, and acellular pertussis) are typically used. For adolescents and adults, other Tdap vaccines are available [3]. Brands such as Adacel are also Tdap vaccines [5].
What is the difference between Boostrix and DTaP vaccines?
DTaP vaccines are generally given to infants and young children, while Boostrix is approved for older children, adolescents, and adults as a booster dose. The 'aP' in DTaP stands for acellular pertussis, indicating it contains specific components of the pertussis bacteria, similar to Boostrix and other adult Tdap vaccines [3][5].
Who should not get Boostrix?
Individuals who have had a severe allergic reaction to a previous dose of a tetanus, diphtheria, or pertussis vaccine, or to any component of the vaccine, should not receive Boostrix [2]. Those with a history of Arthrogyposis Multiplex Congenita have also been considered for specific vaccine recommendations [6]. It is always recommended to discuss any health concerns or previous reactions with a healthcare provider before vaccination [2].
What are the side effects of Boostrix?
Common side effects of Boostrix can include pain, redness, or swelling at the injection site, as well as mild fever, headache, fatigue, nausea, vomiting, and diarrhea [2]. More serious side effects are rare but can occur [3].
What clinical data supports Boostrix's effectiveness?
Clinical trials have demonstrated the immunogenicity and safety of Boostrix. Studies have shown that it elicits protective antibody responses against tetanus, diphtheria, and pertussis antigens in the target age group [2].
Sources:
[1] https://www.gsk.com/
[2] https://www.fda.gov/vaccines-blood-biologics/approved-information-for-product-recipients-and-caregivers/boostrix-hp-package-insert
[3] https://www.cdc.gov/vaccines/vpd/dtap-tdap/public/index.html
[4] https://www.drugpatentwatch.com/
[5] https://www.fda.gov/vaccines-blood-biologics/approved-information-for-product-recipients-and-caregivers/adacel-package-insert
[6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2760597/